AstraZeneca PLC (LSE:AZN) - Share price


Stock Report

AstraZeneca PLC AZN

Last Price
GBX8,549.00

Day Change
-19.00|-0.22%

As of 14/07/2020
18:30:34 BST | GBX
Minimum 15 Minutes Delay.

Last Close8,568.00p
Day Range8,410.00 - 8,617.00
Mkt Cap112.40Bil
52-Wk Range5,871.00 - 9,537.09
Yield %2.57
ISINGB0009895292
Volume1,565,654
P/E93.46
P/S4.56
P/CF37.46

Share Price

Total Returns 14/07/2020

 Chg (%)  
More ...
AstraZeneca PLC-0.22 
FTSE 100 TR GBP0.06
 
Financials
201720182019
More ...
Income Statement
Turnover22,465.0022,090.0024,384.00
Operating Profit2,710.001,950.001,702.00
Net Profit2,868.002,050.001,227.00
Reported EPS2.371.701.03
Balance Sheet
Current Assets13,150.0014,609.0015,493.00
Non Current Assets50,204.0045,060.0045,814.00
Total Assets63,354.0060,651.0061,377.00
Current Liabilities16,383.0016,292.0018,117.00
Total Liabilities---
Total Equity16,642.0014,044.0014,596.00
Cash Flow
Operating Cash Flow4,032.003,155.004,087.00
Net Change in Cash-1,686.001,537.00547.00

Regulatory News

DateAuthor Headline
09/07/2020James Gard Top 20 FTSE Dividend Paying Stocks
UPDATED July 2020: Most companies on our list have decent dividend cover, but yields are falling across the board after this year's cuts
29/10/2019James Gard Brexit Investment Strategies for Uncertain Times
With a General Election slated for December and Brexit postponed until 2020, investors should consider how their portfolios are positioned for more months of uncertainty 
24/07/2019James Gard Glaxo's Vaccines Division Outperforms
FTSE 100 dividend stalwart posts steady results in the first six months and expects better performance in the second half, during which the joint venture with Pfizer will complete
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
27/03/2020Transfer inMr. Marc Dunoyer0.0019,4290.00
27/03/2020Transfer inMr. Pascal Soriot0.0074,6980.00
24/03/2020Transfer inMr. Marc Dunoyer0.002,3440.00
24/03/2020Transfer inMr. Pascal Soriot0.007,3380.00

Company Profile

AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.

Sector

Drug Manufacturers - General

Index

FTSE 100 ,FTSE 350 ,FTSE All Share ,FTSE Eurotop 100 ,FTSE Eurotop 300

Next Event 30/07/2020

Half-Yearly Results
Ratios
Comp
More ...
PER (E)90.13
Div Yld (E)2.59
PEG (E)1.46
ROCE5.50
Op Mrgn0.07
EPS Grwth-0.64
Dividends
PreviousLatest
More ...
Record Date09/08/1928/02/20
Ex-Div08/08/1927/02/20
Paid09/09/1930/03/20
Amnt71.90146.40
Directors
More ...
Non-Executive DirectorMs. Sherilyn S. (Sheri) McCoy
Non-Executive Director, ChairmanMr. Leif Johansson
Executive Director, Chief Financial OfficerMr. Marc Dunoyer
Non-Executive DirectorMr. Marcus Wallenberg
Non-Executive DirectorMr. Michel Demare
Executive Director, Chief Executive OfficerMr. Pascal Soriot
Non-Executive DirectorPhilip A J Broadley
Non-Executive Director, Senior independent DirectorMr. Graham Andrew Chipchase
Non-Executive DirectorProf Genevieve Berger
Non-Executive DirectorDeborah DiSanzo
Non-Executive DirectorProfessor Nazneen Rahman
Non-Executive DirectorProfessor Tony Mok
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2020 Morningstar. All rights reserved.